AstraZeneca PLC - Product Pipeline Review - 2014

Published: Jun, 2014 | Pages: 328 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

AstraZeneca PLC - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'AstraZeneca PLC - Product Pipeline Review - 2014', provides an overview of the AstraZeneca PLC's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of AstraZeneca PLC's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of AstraZeneca PLC including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of AstraZeneca PLC's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the AstraZeneca PLC's pipeline products

Reasons to buy

- Evaluate AstraZeneca PLC's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of AstraZeneca PLC in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the AstraZeneca PLC's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of AstraZeneca PLC and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of AstraZeneca PLC
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of AstraZeneca PLC and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
AstraZeneca PLC Snapshot 7
AstraZeneca PLC Overview 7
Key Information 7
Key Facts 7
AstraZeneca PLC - Research and Development Overview 8
Key Therapeutic Areas 8
AstraZeneca PLC - Pipeline Review 19
Pipeline Products by Stage of Development 19
Pipeline Products - Monotherapy 20
Pipeline Products - Combination Treatment Modalities 21
Pipeline Products - Partnered Products 22
Pipeline Products - Out-Licensed Products 25
AstraZeneca PLC - Pipeline Products Glance 27
AstraZeneca PLC - Late Stage Pipeline Products 27
AstraZeneca PLC - Clinical Stage Pipeline Products 31
AstraZeneca PLC - Early Stage Pipeline Products 37
AstraZeneca PLC - Drug Profiles 41
(dapagliflozin + metformin hydrochloride) XR 41
(saxagliptin + metformin hydrochloride) 43
cangrelor 45
dapagliflozin 47
naloxegol 50
olaparib 52
ticagrelor 54
vandetanib 57
(budesonide + formoterol) 63
(ceftazidime + avibactam) 64
(glycopyrrolate + formoterol fumarate) 66
(saxagliptin + dapagliflozin) 68
AZD-9291 69
budesonide ER 70
ceftaroline fosamil 72
fulvestrant 74
gefitinib 76
glycopyrrolate 81
lesinurad 82
metreleptin 84
propofol 86
PT-005 87
quetiapine fumarate ER 89
selumetinib sulfate 90
tenapanor 93
(ceftaroline + avibactam) 95
AZD-1775 97
AZD-1981 99
AZD-2014 100
AZD-2115 101
AZD-3241 102
AZD-4017 103
AZD-4547 105
AZD-4901 106
AZD-5069 107
AZD-5213 108
AZD-5363 109
AZD-5847 111
AZD-9150 113
DSP-3025 114
exenatide Once Monthly 116
HMPL-504 118
Omega-3-carboxylic acids 120
PT-008 122
RDEA-3170 123
saracatinib 124
AZD-1480 126
sapitinib 127
(glycopyrrolate + formoterol fumarate + budesonide) 129
AZD-0424 131
AZD-0914 132
AZD-1208 133
AZD-1979 135
AZD-3293 136
AZD-3965 137
AZD-4721 138
AZD-5312 139
AZD-6423 140
AZD-6738 141
AZD-7451 142
AZD-7624 143
AZD-8186 144
BMS-820132 145
disufenton sodium 146
MEDI-1814 149
MEDI-4893 150
MEDI-8111 152
PEG-FGF21 153
264-RAD 154
900 Series 155
AC-163794 156
AR-A-014418 157
AZ-1 158
AZ-12441970 159
AZ-2 160
AZ-4217 161
AZ-4425 162
AZ-64 163
AZ-709 164
AZ-876 165
AZ-889 166
AZD-2098 167
AZD-2858 168
AZD-3463 169
AZD-9708 170
Drug 1 for Cancer 171
Drug 2 for Cancer 172
Drug 3 for Cancer 173
Drug 4 for Cancer 174
Drug 5 for Cancer 175
Drug 6 for Cancer 176
KU-0060648 177
KU-59403 178
NKTR-119 179
Program 1 for Cancer 180
Program 2 for Cancer 181
pyrrolamide-4 182
R-256 183
RDEA-684 184
Small Molecule to Agonize Melanocortin 4 Receptor for Metabolic Disorders 185
Small Molecule to Inhibit PI3K Beta for Clotting Disorders 186
Small Molecule to Inhibit Xanthine Oxidase for Hyperuricemia 187
Small Molecules for Malaria 188
Small Molecules to Antagonize P2X3 for Chronic Pain 189
Small molecules To Inhibit CDK9 for Central Nervous System and Immunology 190
Small Molecules to Inhibit DNA GyrB for Tuberculosis 191
Small Molecules to Inhibit DprE1 for Mycobacterium Tuberculosis 192
XL-475 193
Aminopyrazinamides 194
AZ-10047130 195
AZ-10776241 196
AZ-82 197
AZD-2738 198
Drugs for Cardiovascular Diseases 199
Drugs for Multi Drug Resistant Tuberculosis 200
Fosmidomycin Analogues 201
Small Molecule to Inhibit Src Tyrosine Kinase for Lymphangioleiomyomatosis 202
Small Molecules for Tuberculosis 203
Small Molecules to Induce Senescence for Cancer 204
Small Molecules to Inhibit ATP Synthesis for Tuberculosis 205
AstraZeneca PLC - Pipeline Analysis 206
AstraZeneca PLC - Pipeline Products by Target 206
AstraZeneca PLC - Pipeline Products by Route of Administration 213
AstraZeneca PLC - Pipeline Products by Molecule Type 214
AstraZeneca PLC - Pipeline Products by Mechanism of Action 215
AstraZeneca PLC - Recent Pipeline Updates 222
AstraZeneca PLC - Dormant Projects 273
AstraZeneca PLC - Discontinued Pipeline Products 280
Discontinued Pipeline Product Profiles 285
AstraZeneca PLC - Company Statement 307
AstraZeneca PLC - Locations And Subsidiaries 309
Head Office 309
Other Locations & Subsidiaries 309
AstraZeneca PLC - Key Manufacturing Facilities 314
Appendix 315
Methodology 315
Coverage 315
Secondary Research 315
Primary Research 315
Expert Panel Validation 315
Contact Us 316
Disclaimer 316

List of Tables
AstraZeneca PLC, Key Information 19
AstraZeneca PLC, Key Facts 19
AstraZeneca PLC - Pipeline by Indication, 2014 22
AstraZeneca PLC - Pipeline by Stage of Development, 2014 31
AstraZeneca PLC - Monotherapy Products in Pipeline, 2014 32
AstraZeneca PLC - Combination Treatment Modalities in Pipeline, 2014 33
AstraZeneca PLC - Partnered Products in Pipeline, 2014 34
AstraZeneca PLC - Partnered Products/ Combination Treatment Modalities, 2014 35
AstraZeneca PLC - Out-Licensed Products in Pipeline, 2014 37
AstraZeneca PLC - Out-Licensed Products/ Combination Treatment Modalities, 2014 38
AstraZeneca PLC - Pre-Registration, 2014 39
AstraZeneca PLC - Filing rejected/Withdrawn, 2014 40
AstraZeneca PLC - Phase III, 2014 41
AstraZeneca PLC - Phase II, 2014 43
AstraZeneca PLC - Phase I, 2014 46
AstraZeneca PLC - Preclinical, 2014 49
AstraZeneca PLC - Discovery, 2014 52
AstraZeneca PLC - Pipeline by Target, 2014 219
AstraZeneca PLC - Pipeline by Route of Administration, 2014 225
AstraZeneca PLC - Pipeline by Molecule Type, 2014 226
AstraZeneca PLC - Pipeline Products by Mechanism of Action, 2014 228
AstraZeneca PLC - Recent Pipeline Updates, 2014 234
AstraZeneca PLC - Dormant Developmental Projects,2014 285
AstraZeneca PLC - Discontinued Pipeline Products, 2014 292
AstraZeneca PLC, Subsidiaries 321
AstraZeneca PLC, Key Manufacturing Facilities 326